Faculty, Staff and Student Publications

Publication Date

1-1-2024

Journal

Nature Medicine

DOI

10.1038/s41591-023-02717-6

PMID

38177853

PMCID

PMC11135132

PubMedCentral® Posted Date

July 2024

PubMedCentral® Full Text Version

Author MSS

Abstract

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRAS

Keywords

Humans, Panitumumab, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Colorectal Neoplasms, ErbB Receptors, Mutation, Antineoplastic Combined Chemotherapy Protocols, Piperazines, Pyridines, Pyrimidines

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.